

Status: Point in time view as at 07/01/2015.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, Part I. (See end of Document for details)

SCHEDULES

SCHEDULE 2

CONTROLLED DRUGS

PART I

CLASS A DRUGS

- 1 The following substances and products, namely:—
- [^{F1}(a)] Acetorphine.
[^{F2}Alfentanil.]
Allylprodine.
Alphacetylmethadol.
Alphameprodine.
Alphamethadol.
Alphaprodine.
Anileridine.
Benzethidine.
Benzylmorphine (3-benzylmorphine).
Betacetylmethadol.
Betameprodine.
Betamethadol.
Betaprodine.
Bezitramide.
Bufotenine.
^{F3} ...
^{F4} ...
[^{F5}Carfentanil.]
Clonitazene.
Coca leaf.
Cocaine.
Desomorphine.
Dextromoramide.
Diamorphine.
Diampromide.
Diethylthiambutene.
[^{F6}Difenoxin (1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylic acid).]
Dihydrocodeinone-*O*-carboxymethyloxime.

Status: Point in time view as at 07/01/2015.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, Part 1. (See end of Document for details)

[^{F7}Dihydroetorphine]

Dimenoxadole.

Dimepheptanol.

Dimethylthiambutene.

Dioxaphetyl butyrate.

Diphenoxylate.

Dipipanone.

[^{F8}Drotebanol (3,4-dimethoxy-17-methylmorphinan-6b, 14-diol).]

Ecgonine, and any derivative of ecgonine which is convertible to ecgonine or to cocaine.

Ethylmethylthiambutene.

[^{F2}Eticyclidine.]

Etonitazene.

Etorphine.

Etoxadine.

[^{F9}Etryptamine]

Fentanyl.

[^{F10}Fungus (of any kind) which contains psilocin or an ester of psilocin.]

Furethidine.

Hydrocodone.

Hydromorphinol.

Hydromorphone.

Hydroxypethidine.

Isomethadone.

Ketobemidone.

Levomethorphan.

Levomoramide.

Levophenacylmorphan.

Levorphanol.

[^{F5}Lofentanil]

Lysergamide.

Lysergide and other *N*-alkyl derivatives of lysergamide.

Mescaline.

Metazocine.

Methadone.

Methadyl acetate.

[^{F11}Methylamphetamine]

Methyldesorphine.

Methyldihydromorphine (6-methyldihydromorphine).

Metopon.

Morpheridine.

Morphine.

Morphine methobromide, morphine *N*-oxide and other pentavalent nitrogen morphine derivatives.

Status: Point in time view as at 07/01/2015.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, Part 1. (See end of Document for details)

Myrophine.

F12
. . .

Nicomorphine (3,6-dinicotinoylmorphine).

Noracymethadol.

Norlevorphanol.

Normethadone.

Normorphine.

Norpipanone.

Opium, whether raw, prepared or medicinal.

Oxycodone.

Oxymorphone.

Pethidine.

Phenadoxone.

Phenampromide.

Phenazocine.

[F13Phencyclidine.]

Phenomorphane.

Phenoperidine.

Piminodine.

Piritramide.

Poppy-straw and concentrate of poppy-straw.

Proheptazine.

Properidine (1-methyl-4-phenyl-piperidine-4-carboxylic acid
isopropyl ester).

Psilocin.

Racemethorphan.

Racemoramide.

Racemorphan.

[F14Remifentanil]

[F2Rolicyclidine.]

[F15Sufentanil.]

[F16Tapentadol.]

[F2Tenocyclidine.]

Thebacon.

Thebaine.

[F15Tilidate.]

Trimeperidine.

[F17(6aR,9R)-4-acetyl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-
hexahydroindolo[4,3-fg]quinoline-9-carboxamide (ALD-52).]

[F184-Bromo-2,5-dimethoxy-a-methylphenethylamine].

4-Cyano-2-dimethylamino-4,4-diphenylbutane.

4-Cyano-1-methyl-4-phenyl-piperidine.

[F193,4-dichloro-N-[[1-
(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921);

Status: Point in time view as at 07/01/2015.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, Part 1. (See end of Document for details)

(6aR,9R) *R*,9 *R*)- *N,N*-diethyl-7-allyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinoline-9-carboxamide (AL-LAD);
(6aR,9R) *R*,9*R*)-*N,N*-diethyl-7-ethyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinoline-9-carboxamide (ETH-LAD);
(6aR,9R)*R*,9*R*)-*N,N*-diethyl-7-propyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinoline-9-carboxamide (PRO-LAD).]
N,N-Diethyltryptamine.

[^{F20}2,4-dimethylazetidiny]l{(6aR,9R)-7-methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-*fg*]quinolin-9-yl}methanone (LSZ).]
N,N-Dimethyltryptamine.

2,5-Dimethoxy-*a*,4-dimethylphenethylamine.

[^{F21}N-Hydroxy-tenamphetamine.]

1-Methyl-4-phenylpiperidine-4-carboxylic acid.

2-Methyl-3-morpholino-1, 1-diphenylpropanecarboxylic acid.

[^{F22}4-Methyl-aminorex]

4-Phenylpiperidine-4-carboxylic acid ethyl ester.

[^{F23}(b) any compound (not being a compound for the time being specified in subparagraph (a) above) structurally derived from tryptamine or from a ring-hydroxy tryptamine by modification in any of the following ways, that is to say—

- (i) by substitution at the nitrogen atom of the sidechain to any extent with alkyl or alkenyl substituents, or by inclusion of the nitrogen atom of the side chain (and no other atoms of the side chain) in a cyclic structure;
- (ii) by substitution at the carbon atom adjacent to the nitrogen atom of the side chain with alkyl or alkenyl substituents;
- (iii) by substitution in the 6-membered ring to any extent with alkyl, alkoxy, haloalkyl, thioalkyl, alkylenedioxy, or halide substituents;
- (iv) by substitution at the 2-position of the tryptamine ring system with an alkyl substituent;]

[^{F24}(ba) the following phenethylamine derivatives, namely:—

Allyl(*a* -methyl-3,4-methylenedioxyphenethyl)amine

2-Amino-1-(2,5-dimethoxy-4-methylphenyl)ethanol

2-Amino-1-(3,4-dimethoxyphenyl)ethanol

Benzyl(*a* -methyl-3,4-methylenedioxyphenethyl)amine

4-Bromo- *b* ,2,5-trimethoxyphenethylamine

N -(4- *sec* -Butylthio-2,5-dimethoxyphenethyl)hydroxylamine

Cyclopropylmethyl(*a* -methyl-3,4-methylenedioxyphenethyl)amine

2-(4,7-Dimethoxy-2,3-dihydro-1 *H* -indan-5-yl)ethylamine

2-(4,7-Dimethoxy-2,3-dihydro-1 *H* -indan-5-yl)-1-methylethylamine

2-(2,5-Dimethoxy-4-methylphenyl)cyclopropylamine

2-(1,4-Dimethoxy-2-naphthyl)ethylamine

2-(1,4-Dimethoxy-2-naphthyl)-1-methylethylamine

N -(2,5-Dimethoxy-4-propylthiophenethyl)hydroxylamine

2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)ethylamine

2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine

Status: Point in time view as at 07/01/2015.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, Part 1. (See end of Document for details)

a, *a* -Dimethyl-3,4-methylenedioxyphenethylamine
a, *a* -Dimethyl-3,4-methylenedioxyphenethyl(methyl)amine
Dimethyl(*a* -methyl-3,4-methylenedioxyphenethyl)amine
N -(4-Ethylthio-2,5-dimethoxyphenethyl)hydroxylamine
4-Iodo-2,5-dimethoxy- *a* -methylphenethyl(dimethyl)amine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)ethylamine
2-(1,4-Methano-5,8-dimethoxy-1,2,3,4-tetrahydro-6-naphthyl)-1-methylethylamine
2-(5-Methoxy-2,2-dimethyl-2,3-dihydrobenzo[*b*]furan-6-yl)-1-methylethylamine
2-Methoxyethyl(*a* -methyl-3,4-methylenedioxyphenethyl)amine
2-(5-Methoxy-2-methyl-2,3-dihydrobenzo[*b*]furan-6-yl)-1-methylethylamine
b -Methoxy-3,4-methylenedioxyphenethylamine
1-(3,4-Methylenedioxybenzyl)butyl(ethyl)amine
1-(3,4-Methylenedioxybenzyl)butyl(methyl)amine
2-(*a* -Methyl-3,4-methylenedioxyphenethylamino)ethanol
a -Methyl-3,4-methylenedioxyphenethyl(prop-2-ynyl)amine
N -Methyl- *N* -(*a* -methyl-3,4-methylenedioxyphenethyl)hydroxylamine
O -Methyl- *N* -(*a* -methyl-3,4-methylenedioxyphenethyl)hydroxylamine
a -Methyl-4-(methylthio)phenethylamine
b, 3,4,5-Tetramethoxyphenethylamine
b, 2,5-Trimethoxy-4-methylphenethylamine;]

[^{F25}(c) any compound (not being methoxyphenamine or a compound for the time being specified in sub-paragraph (a) above) structurally derived from phenethylamine an *N* -alkylphenethylamine, a-methylphenethylamine, an *N* -alkyl-a-methylphenethylamine, a-ethylphenethylamine, or an *N* -alkyl-a-ethylphenethylamine by substitution in the ring to any extent with alkyl, alkoxy, alkylendioxy or halide substituents, whether or not further substituted in the ring by one or more other univalent substituents.]

[^{F26}(d) any compound (not being a compound for the time being specified in sub-paragraph (a) above) structurally derived from fentanyl by modification in any of the following ways, that is to say,

- (i) by replacement of the phenyl portion of the phenethyl group by any heteromonocycle whether or not further substituted in the heterocycle;
- (ii) by substitution in the phenethyl group with alkyl, alkenyl, alkoxy, hydroxy, halogeno, haloalkyl, amino or nitro groups;
- (iii) by substitution in the piperidine ring with alkyl or alkenyl groups;
- (iv) by substitution in the aniline ring with alkyl, alkoxy, alkylendioxy, halogeno or haloalkyl groups;
- (v) by substitution at the 4-position of the piperidine ring with any alkoxy-carbonyl or alkoxyalkyl or acyloxy group;
- (vi) by replacement of the N-propionyl group by another acyl group;

Status: Point in time view as at 07/01/2015.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, Part I. (See end of Document for details)

- (e) any compound (not being a compound for the time being specified in subparagraph (a) above) structurally derived from pethidine by modification in any of the following ways, that is to say,
- (i) by replacement of the 1-methyl group by an acyl, alkyl whether or not unsaturated, benzyl or phenethyl group, whether or not further substituted;
 - (ii) by substitution in the piperidine ring with alkyl or alkenyl groups or with a propano bridge, whether or not further substituted;
 - (iii) by substitution in the 4-phenyl ring with alkyl, alkoxy, aryloxy, halogeno or haloalkyl groups;
 - (iv) by replacement of the 4-ethoxycarbonyl by any other alkoxy carbonyl or any alkoxyalkyl or acyloxy group;
 - (v) by formation of an N-oxide or of a quaternary base.]
- [^{F27}(f) any compound (not being benzyl(α -methyl-3,4-methylenedioxyphenethyl)amine) structurally derived from mescaline, 4-bromo-2,5-dimethoxy- α -methylphenethylamine, 2,5-dimethoxy- α ,4-dimethylphenethylamine, *N*-hydroxytenamphetamine, or a compound specified in sub-paragraph (ba) or (c) above, by substitution at the nitrogen atom of the amino group with a benzyl substituent, whether or not substituted in the phenyl ring of the benzyl group to any extent.]

Textual Amendments

- F1** "(a)" inserted by [S.I. 1977/1243](#), [art. 3\(a\)](#)
- F2** Word inserted by [S.I. 1984/859](#), [art. 2\(2\)](#)
- F3** Words in Sch. 2 Pt. 1 para. 1(a) deleted (29.1.2004) by [The Misuse of Drugs Act 1971 \(Modification\) \(No. 2\) Order 2003 \(S.I. 2003/3201\)](#), [art. 2\(2\)](#)
- F4** Words in Sch. 2 Pt. 1 para. 1(a) deleted (29.1.2004) by [The Misuse of Drugs Act 1971 \(Modification\) \(No. 2\) Order 2003 \(S.I. 2003/3201\)](#), [art. 2\(2\)](#)
- F5** Word inserted by [S.I. 1986/2230](#), [art. 2\(2\)\(a\)](#)
- F6** Word inserted by [S.I. 1975/421](#), [art. 3](#)
- F7** Word in Sch. 2 Pt. 1 para. 1(a) inserted (1.7.2003) by [The Misuse of Drugs Act 1971 \(Modification\) Order 2003 \(S.I. 2003/1243\)](#), [art. 2\(2\)\(a\)](#)
- F8** Word inserted by [S.I. 1973/771](#), [art. 2](#)
- F9** Word in Sch. 2 Pt. 1 para. 1(a) inserted (1.5.1998) by [S.I. 1998/750](#), [art. 2\(2\)](#)
- F10** Words in Sch. 2 Pt. 1 para. 1 inserted (18.7.2005) by [Drugs Act 2005 \(c. 17\)](#), [s. 21](#)
- F11** Word in Sch. 2 Pt. 1 para. 1(a) inserted (18.1.2007) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2006 \(S.I. 2006/3331\)](#), [art. 2\(1\)](#)
- F12** Words repealed by [S.I. 1973/771](#), [art. 2](#)
- F13** Word inserted by [S.I. 1979/299](#), [art. 2](#)
- F14** Word in Sch. 2 Pt. 1 para. 1(a) inserted (1.7.2003) by [The Misuse of Drugs Act 1971 \(Modification\) Order 2003 \(S.I. 2003/1243\)](#), [art. 2\(2\)\(b\)](#)
- F15** Word inserted by [S.I. 1983/765](#), [art. 2\(a\)](#)
- F16** Word in Sch. 2 Pt. 1 para. 1(a) inserted (28.3.2011) by [The Misuse of Drugs Act 1971 \(Amendment\) Order 2011 \(S.I. 2011/744\)](#), [arts. 1\(1\), 2](#)
- F17** Words in Sch. 2 Pt. 1 para. 1(a) inserted (7.1.2015) by [The Misuse of Drugs Act 1971 \(Amendment\) \(No. 2\) Order 2014 \(S.I. 2014/3271\)](#), [art. 3\(a\)](#)
- F18** Words inserted by [S.I. 1975/421](#), [art. 3](#)
- F19** Words in Sch. 2 Pt. 1 para. 1(a) inserted (7.1.2015) by [The Misuse of Drugs Act 1971 \(Amendment\) \(No. 2\) Order 2014 \(S.I. 2014/3271\)](#), [art. 3\(b\)](#)

Status: Point in time view as at 07/01/2015.

Changes to legislation: There are currently no known outstanding effects for the Misuse of Drugs Act 1971, Part I. (See end of Document for details)

- F20** Words in Sch. 2 Pt. 1 para. 1(a) inserted (7.1.2015) by [The Misuse of Drugs Act 1971 \(Amendment\) \(No. 2\) Order 2014 \(S.I. 2014/3271\)](#), **art. 3(c)**
- F21** Word inserted by [S.I. 1990/2589](#), **art. 2(a)(i)**
- F22** Word inserted by [S.I. 1990/2589](#), **art. 2(a)(ii)**
- F23** Sch. 2 Pt. 1 para. 1(b) substituted (7.1.2015) by [The Misuse of Drugs Act 1971 \(Amendment\) \(No. 2\) Order 2014 \(S.I. 2014/3271\)](#), **art. 4**
- F24** Sch. 2 Pt. I para. 1(ba) inserted (1.2.2002) by [The Misuse of Drugs Act 1971 \(Modification\) Order 2001 \(S.I. 2001/3932\)](#), **art. 2(2)**
- F25** Sch. 2 Pt. I para. 1(b)(c) added by [S.I. 1977/1243](#), **art. 3(b)**
- F26** Sch. 2 Pt. I para. 1(d)(e) added by [S.I. 1986/2230](#), **art. 2(2)(b)**
- F27** Sch. 2 Pt. 1 para. 1(f) inserted (10.6.2014) by [The Misuse of Drugs Act 1971 \(Ketamine etc.\) \(Amendment\) Order 2014 \(S.I. 2014/1106\)](#), **art. 3**

- 2 Any stereoisomeric form of a substance for the time being specified in paragraph 1 above not being dextromethorphan or dextrorphan.
- 3 Any ester or ether of a substance for the time being specified in paragraph 1 or 2 above [^{F28}not being a substance for the time being specified in Part II of this Schedule].

Textual Amendments

- F28** Words inserted by [S.I. 1973/771](#), **art. 2**

- 4 Any salt of a substance for the time being specified in any of paragraphs 1 to 3 above.
- 5 Any preparation or other product containing a substance or product for the time being specified in any of paragraphs 1 to 4 above.
- 6 Any preparation designed for administration by injection which includes a substance or product for the time being specified in any of paragraphs 1 to 3 of Part II of this Schedule.

Status:

Point in time view as at 07/01/2015.

Changes to legislation:

There are currently no known outstanding effects for the Misuse of Drugs Act 1971, Part I.